Bio

Jamey Marth is Director of the Center for Nanomedicine and Professor at UC Santa Barbara; and a Professor of the Sanford-Burnham Medical Research Institute. Dr. Marth holds the John Carbon Endowed Chair of Biochemistry and Molecular Biology and the Duncan and Suzanne Mellichamp Endowed Chair of Systems Biology. He is a member of the Department of Molecular, Cellular, and Developmental Biology, and of the Biomolecular Science and Engineering program. He received a Ph.D. degree in Pharmacology from the University of Washington where he studied with Roger M. Perlmutter, previous Executive Vice-President of Research and Development at Amgen, and the late Edwin G. Krebs, a 1992 Nobel laureate. Dr. Marth was recruited to UC San Diego in 1995 by George Palade - a 1974 Nobel laureate, where he was appointed as an Investigator of the Howard Hughes Medical Institute and Professor in the Department of Cellular and Molecular Medicine, prior to his current positions.

Research

Research in the Marth laboratory combines the physical and biological sciences, often bridged by engineering and nanotechnologies, to discover the metabolic origins of common grievous diseases and to devise effective strategies for disease prevention, treatment, and cure. The laboratory is interdiscplinary and technologically innovative with expertise spanning the fields of immunology, microbiology, hematology, genetics, pharmacology, physiology, oncology, glycobiology, and metabolism. The Marth laboratory previously enumerated and published the molecular building blocks of life used to construct the four types of components common to all cells. Research in the Marth laboratory that integrates these components has recently identified unexpected cellular and molecular origins of diabetes, autoimmune and inflammatory diseases, and the lethal complications of infection. Discoveries made are being applied to the development of more effective diagnostics and therapeutics for detecting, preventing, and alleviating these syndromes. In past research, the Marth laboratory conceived and co-developed the Cre-loxP conditional mutagenesis technology – a genetic engineering technique in widespread use to establish the mechanisms of health and disease.